{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:45:52Z","timestamp":1793094352801,"version":"4.5.0"},"reference-count":12,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2021,8,1]]},"DOI":"10.1001\/jamacardio.2021.1157","type":"journal-article","created":{"date-parts":[[2021,5,16]],"date-time":"2021-05-16T12:30:31Z","timestamp":1621168231000},"page":"910","source":"Crossref","is-referenced-by-count":72,"title":["Association Between Achieved \u03c9-3 Fatty Acid Levels and Major Adverse Cardiovascular Outcomes in Patients With High Cardiovascular Risk"],"prefix":"10.1001","volume":"6","author":[{"given":"Steven E.","family":"Nissen","sequence":"first","affiliation":[{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Michael","family":"Lincoff","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Wolski","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christie M.","family":"Ballantyne","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. P.","family":"Kastelein","sequence":"additional","affiliation":[{"name":"Academic Medical Center, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Ridker","sequence":"additional","affiliation":[{"name":"Center for Cardiovascular Disease Prevention, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[{"name":"Imperial College of London, London, England"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren K.","family":"McGuire","sequence":"additional","affiliation":[{"name":"University of Texas Southwestern Medical Center, Dallas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dariush","family":"Mozaffarian","sequence":"additional","affiliation":[{"name":"Friedman School of Nutrition Science and Policy, Tufts University, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Koenig","sequence":"additional","affiliation":[{"name":"Deutsches Herzzentrum M\u00fcnchen, Technische Universit\u00e4t M\u00fcnchen, DZHK (German Centre for Cardiovascular Research) Munich Heart Alliance, Munich, Germany"},{"name":"Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Davidson","sequence":"additional","affiliation":[{"name":"University of Chicago, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Garcia","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian G.","family":"Katona","sequence":"additional","affiliation":[{"name":"AstraZeneca BioPharmaceuticals R&D, Late-stage Development, Cardiovascular, Renal and Metabolic, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Himmelmann","sequence":"additional","affiliation":[{"name":"AstraZeneca BioPharmaceuticals R&D, Late-stage Development, Cardiovascular, Renal and Metabolic, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larrye E.","family":"Loss","sequence":"additional","affiliation":[{"name":"AstraZeneca BioPharmaceuticals R&D, Late-stage Development, Cardiovascular, Renal and Metabolic, Gaithersburg, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Poole","sequence":"additional","affiliation":[{"name":"AstraZeneca BioPharmaceuticals R&D, Late-stage Development, Cardiovascular, Renal and Metabolic, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venu","family":"Menon","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Coordinating Center for Clinical Research, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Nicholls","sequence":"additional","affiliation":[{"name":"Monash Cardiovascular Research Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"hoi210026r1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1812792","article-title":"Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia.","volume":"380","author":"Bhatt","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"hoi210026r2","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1001\/jama.2020.22258","article-title":"Effect of high-dose omega-3 fatty acids vs corn oil on major adverse cardiovascular events in patients at high cardiovascular risk: the STRENGTH randomized clinical trial.","volume":"324","author":"Nicholls","year":"2020","journal-title":"JAMA"},{"issue":"22","key":"hoi210026r4","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1001\/jama.2020.22898","article-title":"Do omega-3 fatty acids benefit health?","volume":"324","author":"Curfman","year":"2020","journal-title":"JAMA"},{"issue":"10","key":"hoi210026r5","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1002\/clc.23055","article-title":"Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.","volume":"41","author":"Nicholls","year":"2018","journal-title":"Clin Cardiol"},{"issue":"6","key":"hoi210026r6","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s11883-010-0133-4","article-title":"Dietary monounsaturated fatty acids appear not to provide cardioprotection.","volume":"12","author":"Degirolamo","year":"2010","journal-title":"Curr Atheroscler Rep"},{"issue":"9177","key":"hoi210026r7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/S0140-6736(99)07072-5","article-title":"Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial.","volume":"354","author":"Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019Infarto miocardico","year":"1999","journal-title":"Lancet"},{"issue":"40","key":"hoi210026r8","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1093\/eurheartj\/ehaa652","article-title":"Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial.","volume":"41","author":"Budoff","year":"2020","journal-title":"Eur Heart J"},{"issue":"1","key":"hoi210026r9","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2008.06.003","article-title":"Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS).","volume":"200","author":"Saito","year":"2008","journal-title":"Atherosclerosis"},{"issue":"4","key":"hoi210026r10","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1056\/NEJMoa1203859","article-title":"n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.","volume":"367","author":"Bosch","year":"2012","journal-title":"N Engl J Med"},{"issue":"16","key":"hoi210026r11","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJMoa1804989","article-title":"Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.","volume":"379","author":"Bowman","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"hoi210026r12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1811403","article-title":"Marine n-3 fatty acids and prevention of cardiovascular disease and cancer.","volume":"380","author":"Manson","year":"2019","journal-title":"N Engl J Med"},{"key":"hoi210026r3","unstructured":"US Food and Drug Administration Briefing Document. Endocrinologic and Metabolic Drugs Advisory Committee Meeting November 14, 2019. Accessed April 9, 2021. https:\/\/www.fda.gov\/media\/132477\/download"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2779978\/jamacardiology_nissen_2021_oi_210026_1628256761.78592.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T20:08:01Z","timestamp":1628539681000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2779978"}},"subtitle":["A Secondary Analysis of the STRENGTH Trial"],"short-title":[],"issued":{"date-parts":[[2021,8,1]]},"references-count":12,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2021.1157","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8,1]]}}}